Consensus for FY24 EPS is $3.96. Raises FY24 revenue view to $970M-$1.02B from $935M-$1.015B, consensus $983.85M. Sees FY24 adjusted EBITDA $595M-$625M, representing growth of 40% to 47% over 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme reports Q3 non-GAAP EPS $1.27, consensus 98c
- HALO Earnings this Week: How Will it Perform?
- Halozyme provides update following EPO decision to revoke Darzalex patent
- Halozyme downgraded to Equal Weight from Overweight at Wells Fargo
- Halozyme announces expansion of global collaboration with argenx